Heart Transplant — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Heart transplantation is the surgical replacement of a patient's irreversibly failing heart with a healthy donor heart procured from a brain-dead or circulatory-death donor and preserved in cold cardioplegic solution. It is the definitive treatment for end-stage heart failure when all medical therapies — including guideline-directed medication optimisation, cardiac resynchronisation therapy, and implantable cardioverter-defibrillator placement — have been exhausted and the patient's predicted one-year survival on continued medical management is below fifty percent. The first successful human-to-human heart transplant was performed by Christiaan Barnard in Cape Town in 1967, and the procedure entered mainstream clinical practice following the introduction of cyclosporine-based immunosuppression in the early 1980s. Approximately five thousand heart transplants are performed worldwide annually, with major centres in the United States, United Kingdom, Germany, France, and Australia. The procedure requires a multidisciplinary transplant team including cardiothoracic surgeons, cardiologists, immunologists, anaesthesiologists, intensive care specialists, and specialist transplant coordinators. Patient selection, organ allocation, and post-transplant management are governed by national transplant organisations (UNOS in the USA, NHS Blood and Transplant in the UK) operating under donor-recipient matching algorithms based on blood type, body size, urgency status, and geographical proximity.

Heart transplantation is indicated for end-stage heart failure with NYHA Class III–IV symptoms despite optimal medical and device therapy, an ejection fraction typically below twenty-five percent, and a predicted one-year survival below fifty percent by validated models (SHFM, MAGGIC). The most common underlying diagnoses are dilated cardiomyopathy and ischaemic cardiomyopathy. Other indications include refractory life-threatening ventricular arrhythmias, cardiac amyloidosis, hypertrophic cardiomyopathy with end-stage remodelling, and congenital heart disease not amenable to further surgical correction. Absolute contraindications include irreversible pulmonary hypertension (pulmonary vascular resistance above six Wood units unresponsive to vasodilator testing — a fixed elevated resistance would cause acute right heart failure in the new heart), active systemic infection, active or recent malignancy within five years (exceptions for certain low-grade cancers), severe irreversible renal, hepatic, or neurological dysfunction, ongoing alcohol or substance misuse, severe morbid obesity (BMI above thirty-five), and inadequate psychosocial support. Relative contraindications include age above seventy, diabetes with end-organ damage, peripheral or cerebrovascular disease, and chronic renal impairment. Patients deemed too ill for conventional transplant may be bridged with a left ventricular assist device (LVAD) while awaiting a suitable donor organ.

The recipient undergoes median sternotomy under general anaesthesia. Cardiopulmonary bypass (CPB) is established by cannulating the ascending aorta and venae cavae. The failing recipient heart is excised, leaving the posterior walls of the left and right atria in situ. The donor heart — preserved in cold cardioplegia solution at four degrees Celsius and transported in an insulated container, with a maximum acceptable cold ischaemic time of four to six hours — is implanted using four sequential anastomoses: first the left atrium (recipient posterior wall to donor left atrium), then the right atrium or bicaval anastomoses (superior and inferior venae cavae), then the aorta, and finally the pulmonary artery. Air is vented from the cardiac chambers before aortic cross-clamp removal. The heart is defibrillated or resumes beating spontaneously as warm blood flows through the coronary arteries. Bypass support is progressively weaned as the new heart assumes the circulatory load, assisted initially by inotropic agents (adrenaline, noradrenaline, dobutamine) and temporarily by an intra-aortic balloon pump if necessary. Haemostasis is confirmed and the sternotomy is closed. Total operative time is four to eight hours; bypass time is typically ninety to one hundred and eighty minutes depending on anastomotic complexity. Total operative time from skin incision to closure is typically 4–6 hours.

Heart transplantation provides dramatic improvement in both survival and quality of life compared to continued medical management in end-stage heart failure. The International Society for Heart and Lung Transplantation (ISHLT) 2024 registry data reports median post-transplant survival of approximately thirteen to fifteen years — compared to one to two years median survival for Stage D heart failure on optimal medical therapy. One-year survival is approximately eighty-five percent and five-year survival seventy-five percent. Functional improvement is striking: most recipients advance from NYHA Class III–IV before transplantation to Class I–II after recovery, with substantial improvements in six-minute walk distance, peak VO2 on cardiopulmonary exercise testing, and patient-reported quality of life scores. The majority of survivors return to meaningful daily activity, with thirty to forty percent returning to employment or voluntary work within one to two years. Exercise capacity, while below age-matched normals due to cardiac denervation and deconditioning, improves substantially with structured cardiac rehabilitation. Re-transplantation is performed for late graft failure from cardiac allograft vasculopathy in selected recipients with acceptable expected survival benefit.

Heart transplantation carries significant short- and long-term risks inherent to the magnitude of surgery and the requirement for lifelong immunosuppression. Early complications include primary graft dysfunction (PGD) — failure of the donor heart to function adequately in the first twenty-four to forty-eight hours due to ischaemia-reperfusion injury — which occurs in approximately ten to twenty percent of transplants and carries thirty-day mortality exceeding fifty percent in severe cases despite mechanical circulatory support. Acute cellular rejection — recognition and destruction of donor heart tissue by recipient T lymphocytes — occurs in twenty-five to thirty percent of patients in the first year despite triple immunosuppression (calcineurin inhibitor, antiproliferative agent, corticosteroid). Endomyocardial biopsies are performed serially to detect subclinical rejection. Infection is the leading cause of death in the first year, driven by immunosuppression-related vulnerability to bacterial, viral (CMV, EBV), fungal (Pneumocystis, Aspergillus), and opportunistic pathogens. Long-term complications include cardiac allograft vasculopathy (CAV) — a progressive diffuse coronary artery disease of the donor heart caused by chronic immune injury — affecting thirty percent of recipients at five years and sixty percent at ten years; it is the leading cause of late graft failure and death. Calcineurin inhibitor nephrotoxicity causes chronic renal failure requiring dialysis in approximately three to five percent of long-term survivors. Malignancy — particularly skin cancers and post-transplant lymphoproliferative disorder (PTLD) — is three to ten times more frequent than age-matched controls.

Post-operative care begins in the cardiothoracic intensive care unit, where recipients typically spend five to fourteen days. Haemodynamic monitoring, ventilatory support, inotrope management, and infection prophylaxis are the immediate priorities. Mediastinal drains are removed at twenty-four to forty-eight hours when output is minimal. Sternal healing requires avoidance of heavy lifting and overhead arm movements for eight to ten weeks. Endomyocardial biopsy — performed by right-heart catheterisation via the jugular or femoral vein — is the standard method for rejection surveillance, conducted weekly for the first month, then monthly for six months, then less frequently. Lifelong triple immunosuppression with a calcineurin inhibitor (tacrolimus, target trough levels individualised), mycophenolate mofetil (one to two grams per day), and gradually tapering prednisolone is mandatory. Patients receive prophylaxis against CMV (valganciclovir), Pneumocystis jirovecii pneumonia (co-trimoxazole), and oral candidiasis (nystatin or fluconazole) during the high-immunosuppression early period. Cardiac rehabilitation commences at six to eight weeks and continues for three to six months, accommodating the physiological challenge of cardiac denervation — the transplanted heart lacks autonomic neural connections, so heart rate response to exercise is blunted and warm-up and cool-down periods are especially important. Annual coronary angiography monitors for CAV from year one post-transplant, and treatment with everolimus (replacing mycophenolate) may slow its progression.